CRSP - CRISPR Therapeutics AG Stock Price, Fair Value and News

57.87USD+0.30 (+0.52%)Market Closed

Market Summary

USD57.87+0.30

Market Closed

0.52%

CRSP Alerts

1 major insider sales recently.

CRSP Stock Price

View Fullscreen

CRSP RSI Chart

CRSP Valuation

Market Cap

4.9B

Price/Earnings (Trailing)

-22.63

Price/Sales (Trailing)

13.84

EV/EBITDA

-21.55

Price/Free Cashflow

-29.51

CRSP Price/Sales (Trailing)

CRSP Profitability

EBT Margin

-57.88%

Return on Equity

-10.42%

Return on Assets

-8.9%

Free Cashflow Yield

-3.39%

CRSP Fundamentals

CRSP Revenue

Revenue (TTM)

371.2M

CRSP Earnings

Earnings (TTM)

-217.1M

Earnings Growth (Yr)

-119.71%

Earnings Growth (Qtr)

-230.49%

Breaking Down CRSP Revenue

Last 7 days

6.1%

Last 30 days

2.2%

Last 90 days

7.4%

Trailing 12 Months

4.4%

How does CRSP drawdown profile look like?

CRSP Financial Health

Current Ratio

17.81

CRSP Investor Care

Shares Dilution (1Y)

7.58%

Diluted EPS (TTM)

-2.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	697.5M	588.7M	480.0M	371.2M
2022	806.2M	0	0	0
2021	646.9M	736.3M	825.6M	915.0M
2020	0	378.9M	468.3M	557.6M
2019	2.1M	97.9M	193.8M	289.6M
2018	31.5M	22.1M	12.6M	3.1M
2017	7.4M	10.2M	11.0M	41.0M
2016	1.2M	2.1M	3.1M	5.2M
2015	0	0	0	247.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CEO	Dr. Samarth Kulkarni Ph.D.
WEBSITE	crisprtx.com
INDUSTRY	Biotechnology
EMPLOYEES	458

CRISPR Therapeutics AG Frequently Asked Questions

What is the ticker symbol for CRISPR Therapeutics AG? What does CRSP stand for in stocks?

CRSP is the stock ticker symbol of CRISPR Therapeutics AG. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CRISPR Therapeutics AG (CRSP)?

As of Fri Jul 26 2024, market cap of CRISPR Therapeutics AG is 4.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRSP stock?

You can check CRSP's fair value in chart for subscribers.

Is CRISPR Therapeutics AG a good stock to buy?

The fair value guage provides a quick view whether CRSP is over valued or under valued. Whether CRISPR Therapeutics AG is cheap or expensive depends on the assumptions which impact CRISPR Therapeutics AG's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRSP.

What is CRISPR Therapeutics AG's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, CRSP's PE ratio (Price to Earnings) is -22.63 and Price to Sales (PS) ratio is 13.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRSP PE ratio will change depending on the future growth rate expectations of investors.